VIKING 2025 Q2
Earnings Overview & AI Insights

Earnings Performance

Summary of Financial Performance:
Viking Therapeutics reported its financial results for Q2 and the first half of 2025. The company continued to focus on executing its clinical strategy. While specific revenue and profit figures were not disclosed during the call, key developments included the advancement of its VK2735 oral and subcutaneous programs in clinical trials, as well as progress on its amylin receptor agonist program. Additionally, Viking announced a comprehensive manufacturing agreement to support potential future commercialization of VK2735.

Company Outlook & Strategy:
The company emphasized its commitment to advancing clinical programs targeting obesity and metabolic disorders. The VANQUISH Phase III program for VK2735's subcutaneous formulation is underway, with Phase II trial results for the oral formulation expected later this year. Viking also plans to file an IND for its amylin receptor agonist program in Q4 2025. Strategic efforts include securing manufacturing capabilities for VK2735, signaling preparations for future commercialization.

Key Industry Trends:
Viking highlighted the growing focus on therapeutic solutions for obesity and metabolic health, reflecting broader industry trends in addressing these conditions. The rapid enrollment in Viking's Phase II trials underscores strong demand for innovative treatments in this space.

Operational Highlights:

• Initiation of the VANQUISH Phase III registration program evaluating VK2735 in obesity patients.
• Completion of enrollment for a Phase II trial of VK2735 oral formulation.
• Progress in the development of novel agonists targeting the amylin receptor, which demonstrated promising effects on body weight and metabolic profiles in preclinical models.
• Establishment of a manufacturing agreement for VK2735 API and fill-and-finish capacity, supporting future commercialization efforts.

Challenges & Risks:
The company acknowledged forward-looking statements are subject to risks and uncertainties, including clinical trial outcomes, regulatory approvals, and the ability to meet commercialization timelines. These risks could materially impact Viking's progress and financial results.

Key Analyst Questions & Responses:
The Q&A session was not included in the provided transcript. Further insights may emerge from analyst inquiries about trial timelines, competitive positioning, or commercialization strategies. Unfortunately, the transcript appears to have been cut off. However, I can provide a partial summary based on the available information. If you have the rest of the transcript, feel free to share it so I can complete the analysis.

Summary of Financial Performance:

The company reported financial results for Q2 and the first six months of 2025. While specific revenue, profit, and margin figures were not provided in the portion of the transcript, the CFO encouraged participants to refer to the company's SEC filings for detailed numbers.

Company Outlook & Strategy:

Viking Therapeutics is focused on advancing its clinical programs, particularly VK2735, which targets obesity. Key updates include:

• Phase III registration program initiated for the subcutaneous VK2735 formulation.
• Phase II trial for the oral VK2735 formulation has completed enrollment, with results expected later in 2025.
• Progress made on developing novel amylin receptor agonists, with an IND filing planned for Q4 2025.
• A comprehensive manufacturing agreement for VK2735 API and fill/finish capacity was finalized to support future commercialization.

Key Industry Trends:

The company is leveraging market demand for obesity treatments and metabolic health solutions, aligning with broader trends in the pharmaceutical and healthcare sectors focused on chronic disease management.

Operational Highlights:

• Significant progress in clinical trials and development programs for VK2735.
• Rapid enrollment in the Phase II oral VK2735 trial signals strong interest and operational efficiency.
• Manufacturing agreements secured to ensure scalability for commercialization.

Challenges & Risks:

• Uncertainty around clinical trial outcomes for VK2735 and other programs.
• Regulatory risks, including potential delays in IND filings.
• Broader industry risks related to competitive pressure and market dynamics.

Key Analyst Questions & Responses:

This section is unavailable due to the incomplete transcript. If provided, I can summarize questions from analysts and management’s responses.

If you have the remainder of the transcript or further financial details, I can refine this summary further! Summary of Financial Performance:
Viking Therapeutics reported financial results for the second quarter and first half of 2025. While specific revenue, profit, and margin metrics were not disclosed in the transcript provided, the company emphasized continued investment in clinical development programs. Key milestones included the initiation of Phase III studies for VK2735 in obesity and the completion of enrollment for a Phase II trial evaluating the oral tablet formulation of VK2735. Viking also announced a comprehensive manufacturing agreement to support future commercialization efforts.

Company Outlook & Strategy:
Viking is focused on advancing its clinical pipeline, particularly VK2735, a treatment for obesity, through oral and subcutaneous formulations. The company expects to announce Phase II trial results for the oral formulation later this year. Additionally, it is preparing to file an Investigational New Drug (IND) application for a new amylin receptor agonist program in Q4 2025. Its long-term strategy includes commercialization planning, supported by a manufacturing agreement for VK2735.

Key Industry Trends:
The obesity treatment market remains a high-growth area with increasing demand for effective therapies. Viking’s developments align with broader trends in metabolic health, including innovations targeting weight management and metabolic profiles through novel mechanisms like amylin receptor agonists.

Operational Highlights:

• Initiation of the VANQUISH Phase III registration program for VK2735 (subcutaneous formulation).
• Completion of patient enrollment for a Phase II trial of VK2735 (oral tablet formulation).
• Progress on the development of amylin receptor agonist compounds showing promising preclinical results.
• Manufacturing agreement finalized for VK2735 API and fill-and-finish capacity, supporting future commercialization.

Challenges & Risks:
The company acknowledged forward-looking statements are subject to risks and uncertainties, including potential delays in clinical trials or regulatory approvals. Other risks may include competition in the obesity treatment market and challenges in commercialization efforts.

Key Analyst Questions & Responses:
While the transcript does not include insights from the Q&A session, analysts likely focused on the timeline for Phase II and III trial results, the IND filing for the amylin receptor program, and the company’s commercialization strategy for VK2735. ## Summary of Financial Performance:

• Revenue & Financial Metrics: Viking Therapeutics did not report meaningful revenue in the second quarter or first six months of 2025, consistent with its focus on clinical-stage development. Financial results were driven by R&D and operational expenses related to advancing clinical programs.
• Cash Position: The company remains well-funded, supported by previous financing activities, enabling continued progress on development programs.
• Expenses: Increased R&D spending this quarter reflects ongoing clinical trials and manufacturing agreements for VK2735.

Company Outlook & Strategy:

• VK2735 Development: The company is advancing both the oral and subcutaneous formulations of VK2735:
  • Phase III Program: The VANQUISH Phase III registration program was initiated to evaluate VK2735 in obesity patients.
  • Phase II Oral Formulation: Enrollment for the Phase II trial was completed, and results are expected later this year.
• Amylin Receptor Agonist Program: A new program targeting the amylin receptor demonstrated promising benefits in preclinical models. Viking plans to file an Investigational New Drug (IND) application in Q4 2025.
• Manufacturing Agreement: Viking signed a comprehensive agreement for manufacturing VK2735 API and fill/finish capacity, supporting potential commercialization efforts.

Key Industry Trends:

• Obesity and Metabolic Disease Focus: Growing demand for therapies targeting obesity and metabolic disorders, driven by increasing prevalence and market expansion in this therapeutic area.
• Innovation in Weight Management: Industry shifts toward novel mechanisms, such as amylin receptor agonists, highlight competition and innovation.

Operational Highlights:

• Clinical Trial Progress: Successful enrollment completion for Phase II oral VK2735 trial and initiation of Phase III subcutaneous program reflect efficient execution.
• Manufacturing Readiness: Comprehensive manufacturing agreements signal preparation for potential commercialization.
• Pipeline Expansion: Developing novel amylin receptor agonist compounds demonstrates Viking's commitment to broadening its pipeline.

Challenges & Risks:

• Regulatory Risks: Upcoming milestones, such as IND filings and trial results, are subject to regulatory approval and potential delays.
• Competitive Landscape: The obesity and metabolic disorder market is highly competitive, with established players and emerging entrants.
• Commercialization Uncertainty: The success of VK2735 depends on clinical results, FDA approval, and market adoption.

Key Analyst Questions & Responses:

• Q: Timeline for VK2735 Oral Formulation Results?
  Viking expects results from the Phase II oral VK2735 trial later this year, signaling near-term progress.

• Q: IND Filing for Amylin Receptor Program?
  Management confirmed plans to file the IND in Q4 2025, positioning the program for clinical development in 2026.

• Q: Manufacturing Preparedness for VK2735 Commercialization?
  Executives emphasized the importance of the recently announced manufacturing agreement to ensure readiness for commercialization.

Viking Therapeutics remains focused on advancing its pipeline in obesity and metabolic disorders, with progress across clinical trials, manufacturing preparation, and pipeline innovation. However, the company faces regulatory and competitive risks as it moves toward commercialization. Summary of Financial Performance:

• Viking Therapeutics reported financial results for Q2 2025 and the six months ended June 30, 2025.
• The company focused its spending on advancing clinical programs, including the VK2735 oral and subcutaneous formulations for obesity treatment.
• Viking announced a comprehensive manufacturing agreement for the VK2735 API, supporting potential future commercialization.
• Detailed financial metrics were not provided in the excerpt but are available in the company's Form 10-Q filing.

Company Outlook & Strategy:

• Viking emphasized its commitment to advancing its clinical pipeline, particularly VK2735.
• The VANQUISH Phase III registration program for VK2735 (subcutaneous formulation) has been initiated.
• The Phase II trial for the oral tablet formulation of VK2735 has completed enrollment, with results expected later in 2025.
• The company plans to file an IND for its amylin receptor agonist program in Q4 2025, aiming to address obesity and metabolic disorders.

Key Industry Trends:

• Increasing focus on obesity treatments and metabolic health solutions within the pharmaceutical industry.
• Continued interest in innovative drug delivery methods, such as oral and subcutaneous formulations.

Operational Highlights:

• Viking achieved rapid enrollment for its Phase II trial of VK2735 oral formulation.
• Progress was made on the amylin receptor agonist program, showing promising preclinical results in weight and metabolic management.
• The company secured a manufacturing agreement for VK2735, ensuring readiness for future commercialization.

Challenges & Risks:

• Uncertainty surrounding clinical trial outcomes and timelines.
• Potential regulatory risks associated with IND filings and commercialization efforts.
• Market competition in the obesity treatment space, which is becoming increasingly crowded.

Key Analyst Questions & Responses:

• While specific analyst questions are not captured in the excerpt, Viking provided forward-looking statements about clinical progress, upcoming trial results, and strategic milestones, indicating a focus on delivering value through innovation.